Arriving in the field of obesity therapy, retatrutide represents a unique approach. Different from many existing medications, retatrutide operates as a double agonist, simultaneously targeting both GLP-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. This concurrent stimulation promotes multiple beneficial ef